People: Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

18 Oct 2019
Change (% chg)

$-0.39 (-2.82%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Glaub, Kathleen 

Ms. Kathleen Sereda Glaub is no longer Independent Director of Codexis, Inc., effective September 30, 2019. Ms. Glaub brings to our board of directors experience in company-building and business strategy at drug development and technology companies. Ms. Glaub currently serves as Executive Chair of CuraSen Therapeutics, Inc. and also serves as a member of the board of directors of Escient Pharmaceutical and IO Biotechnology and advisory board member to Bailard Healthcare Fund. From August 2014 until its acquisition by Merck in July 2016, Ms. Glaub served as Chief Executive Officer of Afferent Pharmaceuticals, which was a clinical-stage biotechnology company developing treatments for respiratory and urologic disorders and chronic pain. Ms. Glaub also served on the board of directors of Afferent from 2013 through 2016. Previously, from November 2001 to May 2013, Ms. Glaub served as President of Plexxikon Inc., a biopharmaceutical company that was acquired by Daiichi Sankyo in 2011. Prior to Plexxikon, Ms. Glaub served as Chief Financial Officer for Cell Genesys, Inc., a biotechnology company. Prior to Cell Genesys, Ms. Glaub served as the Treasurer of Genentech, Inc., a biotechnology company (“Genentech”), and held various financial and treasury roles at Intel Corporation. Ms. Glaub received her B.A. from the University of California, Berkeley, and her M.B.A. from Northwestern University.

Basic Compensation

Total Annual Compensation, USD 80,000
Restricted Stock Award, USD 84,995
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 164,995

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Bernard Kelley


John Nicols


Gordon Sangster


Laurie Heilmann


Thomas Baruch


Pam Cheng

As Of  31 Dec 2018